Sun Pharma launches alopecia drug Leqselvi in US after settling patent dispute
On Monday, Sun Pharma announced on Monday that the American Biopharma Company Incyte Corporation has prepared a patent order on the hair loss medicine and opened its way to the launch of the United States. Mumbai -based drug producer, who has been in the case since last year, launched a private medicine in the world’s largest pharmaceutical market on Monday.
Leqselvi (oral deurxolitanib) has been shown for the treatment of adults with severe alopecia areata.
In a statement, the company said that under the reconciliation and license agreement, the two companies would ask for the rejection of the cases waiting for the New Jersey region for the New Jersey region.
Sun and Incyte will mutually release each other of all the allegations that may or have been raised in this case. Incyte also US patents no. 9,662.335 and other related patents. This license includes Oral Deurxolitanib for a stable hematology indications, including alopecia Areat.
On the other hand, Sun will pay a preliminary amount to Incyte as well as copyright payments until the end of the patents.
The company did not disclose other conditions of the agreement.
In April 2025, Sun Pharma made a positive decision from the US Court of Federal Circuit Appeal at the launch of Leqselvi and abolishing the restrictions in the launch.
In July 2024, Sun received approval from the US Food and Pharmaceutical Administration. Shortly after the approval of the regulator, Incyte Corporation filed a case against Sun Pharma, claiming that Leqselvi had violated and delayed the launch.
In November 2024, the US New Jersey Regional Court stopped the launch of Leqselvi in the United States until the case was resolved and decided to take a precaution.
Drugs
On Monday, Sun Pharma announced the launch of Leqselvi in a separate version in the USA. The drug will be present for prescription on 8mg tablets in the country.
CEO, Sun Pharma North America CEO Richard Ascroft, said, “As a company that promises to launch new therapeutic options that meet the uncommon needs of patients, it represents an important milestone and an important progress for the Areata community.
Leqselvi showed rapid results in clinical studies with one -third of the patients who regained almost all of their hair up to 24 weeks. Some patients (3%) provided rapidly 80% or more scalp up to 8 weeks.
According to Capital for the vehicle, Leqselvi is expected to be an opportunity of $ 200 million for Sun Pharma 3-4 years after the launch.
Sun Pharma’s shares reached 0.58% higher level La1,681.70 in NSE on Monday.
